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Introduction {#s1}
============

Ambient particulate matter (PM) air pollution contributes substantially to cardiovascular disease morbidity and mortality ([@c13]; [@c36]; [@c56]). Several studies have attributed part of the contribution to prolonged ventricular repolarization, a known risk factor for cardiovascular events ([@c11]; [@c17]; [@c51], [@c52]; [@c59]), as suggested by PM-associated increases in risk of ventricular arrhythmia/sudden cardiac death ([@c14]; [@c34]). Indeed, PM has been associated with increases in QT interval duration (QT) ([@c32]; [@c37]; [@c75]), a quantitative electrocardiographic measure of ventricular repolarization. Although QT prolongation is also related to innate variation in myocardial cation channel proteins ([@c3]) and the rate at which cation gradients across these voltage-gated channels return to their resting potential, genetic susceptibility to (i.e., modification of) PM-associated QT prolongation has not been evaluated.

The Clean Air Act nevertheless requires the U.S. Environmental Protection Agency (EPA) to create National Ambient Air Quality Standards (NAAQS) that protect populations susceptible to the adverse health effects of PM. Mindful of such regulatory obligations and their public health implications, the present study examined genome-wide variation in susceptibility to $\text{PM}_{10}$-associated QT prolongation among nine longitudinally well-characterized and racially/ethnically diverse populations of men and women living in the 48 contiguous states in the United States (U.S. $\text{EPA}\,\text{Regions}\, 1–10$).

Methods {#s2}
=======

Study Design {#s2.1}
------------

The study included 22,158 participants in the Atherosclerosis Risk in Communities Study (ARIC) ([@c2]) and the Women's Health Initiative (WHI) clinical trials ([@c40]) cohorts who were examined between 1986 and 2004. They consented to the use of DNA for genetic research, had genomic data, and had one or more high-quality, non-paced baseline or follow-up electrocardiograms (ECGs). They were not taking antiarrhythmic medication and did not have heart failure, bundle branch block ($\text{QRS}\,\text{interval}\,\text{duration} > 120\,\text{ms}$), or Wolf-Parkinson-White pattern.

ARIC participants included black and white men and women. White WHI participants were drawn from three substudies: the Genome-wide Association Research Network into Effects of Treatment (GARNET) ([@c43]), Modification of PM-Mediated Arrhythmogenesis in Populations (MOPMAP) ([@c41]), and Women\'s Health Initiative Memory Study (WHIMS) ([@c62]). Black and Hispanic WHI participants were drawn from the single nucleotide polymorphism (SNP) Health Association Resource Project (SHARe) ([@c42]).

Electrocardiography {#s2.2}
-------------------

At triennial participant examinations and examination sites, trained and certified technicians used standardized procedures and identical electrocardiographs (MAC PC^TM^; GE Marquette Electronics Inc.) to digitally record and telephonically transmit resting, 10-second, standard, simultaneous 12-lead ECGs to a central laboratory (Epidemiological Cardiology Research Center, Wake Forest School of Medicine, Winston-Salem, NC) for visual inspection, identification of technical errors/inadequate quality, and analysis using the 2001 version of the GE Marquette 12--SL^TM^ program (GE Marquette) ([@c1]; [@c82]). Analysis included reliable estimation of median QT (ms) from the orthogonal XYZ leads and median RR interval duration (RR, ms), i.e., the unit-corrected inverse of heart rate ([@c60]; [@c74]).

Genotyping, Quality Control, and Imputation {#s2.3}
-------------------------------------------

Genotypes of participants determined on the Affymetrix GeneChip SNP Array 6.0, Illumina Human Omni1-Quad v1-0 B, Affymetrix Genome-wide Human CEU I, or Human OmniExpress Exome-8v1_B Genome-wide Human platforms were subjected to platform-specific quality filters (see Table S1). In GARNET, SNP dosage was imputed using BEAGLE ([@c9]) and 1,000 Genomes Project (1000G v3 EUR, 03/2012) reference haplotypes. In the remaining subpopulations, imputation relied on MACH ([@c28]) or Minimac ([@c22]) and HapMap2 CEU reference haplotypes in ARIC, MOPMAP, and WHIMS whites; a 1:1 mix of HapMap2 CEU/YRI in ARIC and WHI SHARe blacks; and all 1000G ancestry samples in SHARe Hispanics. Coordinate ranges for all HapMap 2 (Build 36) SNPs were converted to Build 37 using liftOver ([@c26]).

PM Exposure Estimation {#s2.4}
----------------------

Participant addresses at the time of ECGs were accurately geocoded ([@c79]; [@c80]), and then national-scale, log-normal ordinary kriging and U.S. EPA Air Quality Systems (AQS) monitor data were used to estimate geocoded address-specific, daily mean concentrations of ambient $\text{PM} < 10\;\mu m$ in diameter ($\text{PM}_{10}$) ([@c29]) between 1986 and 2004. Validity of the $\text{PM}_{10}$ exposure-estimation method during this period was evaluated using standard cross-validation statistics: the average prediction error ($\text{PE} = \text{predicated} - {\text{measured}–\text{PM}}_{10}$ concentration at each monitor site), standardized prediction error ($\text{SPE} = \text{PE}\text{divided}\,\text{by}\,\text{its}\,\text{estimated}\,\text{standard}\,\text{error}$), root mean square standardized ($\text{RMSS} = \text{standard}\,\text{deviation}\,\text{of}\text{SPE}\,\text{across}\,\text{sites}$), root mean square prediction error ($\text{RMS} = \text{empirical}\,\text{standard}\,\text{error}\,\text{based}\,\text{on}\,\text{the}\,\text{mean}\,\text{square}\,\text{of}\,\text{the}\,\text{predictions}$), and mathematically calculated standard error (SE). Observed values of PE and SPE near 0, RMSS near 1, and RMS near SE have provided evidence of model validity ([@c29]; [@c30]) and justification for use of the estimates in published studies of $\text{PM}_{10}$--health outcome associations ([@c21]; [@c31]; [@c61]; [@c81]; [@c87]) in which daily concentrations were averaged over the day of and day before each ECG ($\text{lag}_{0 - 1}$). Although comparably estimated and accurate, daily mean concentrations of ambient $\text{PM} < 2.5\;\mu m$ in diameter ($\text{PM}_{2.5}$) were not available until 1999, when EPA AQS monitoring data for $\text{PM}_{2.5}$ became more widely available, monthly mean concentrations of ambient $\text{PM}_{2.5}$ were spatiotemporally estimable at the same geocoded addresses between 1986 and 2004 using generalized additive mixed models, the log-transformed ratio of $\text{PM}_{2.5}$ to predicted $\text{PM}_{10}$, and geographic information system (GIS)-based predictors. A 5- to 10-set, out-of-sample cross-validation of the estimates in which the squared Pearson correlation between excluded monthly observations and model predictions ($\mathit{R}^{2} = 0.68 - 0.77$) suggested that the model performed well ([@c85]).

Statistical Analysis {#s2.5}
--------------------

The population was stratified by study, race/ethnicity, and sex. Within these subpopulations, modeling involved a generalized estimating-equations method implemented in R (via the *boss* package) ([@c76]) that was designed to detect interactions between SNPs and low-prevalence environmental exposures on a genome-wide scale using repeated measures data ([@c64]), in which $i$ and $j$ denote the *i*^th^ participant at the *j*^th^ electrocardiographic examination. Models were given by $$QT_{ij} = \beta_{0} + \beta_{1}G_{i} + \beta_{2}E_{ij} + \beta_{3}G_{i}xE_{ij} + \beta_{4}C_{ij},$$ where $QT_{ij}$ is QT (ms); $\beta_{0}$ is the intercept; $G_{i}$ is the HapMap 2 SNP dosage (0--2); $E_{ij}$ is the dichotomized $\text{PM}_{10}$ concentration ($\leq \text{or} >$ an *a* *priori* threshold for abnormality, defined as the subpopulation-specific 90th percentile); $G_{i}xE_{ij}$ is the additive interaction term $\text{SNP} \times \text{PM}_{10}$, and $\beta_{4}$ is a vector of $\beta$ coefficients corresponding to $C_{ij}$, a vector of covariables comprising age (years), geographic region (in WHI) or center (in ARIC), season, calendar year, RR interval (ms), and principal components of ancestry estimated using Eigenstrat ([@c47]). Fit of the fully adjusted model to dichotomized $\text{PM}_{10}$ concentrations reinforced its selection over alternatives expressing QT as a linear, quadratic, linear spline, or quadratic spline function of $\text{PM}_{10}$ with one to five knots, with and without restriction ([@c20]; [@c44]). To reduce type-1 errors in detecting $\text{SNP} \times \text{PM}_{10}$ interactions at low-prevalence exposure, the *t*-reference distribution with degrees of freedom based on Satterthwaite's approximation was used ([@c45]; [@c58]; [@c64]). SNPs with a low minor allele frequency and imputation quality also were excluded from subpopulation-specific analyses ([@c64]) when $$2 \times MAF \times IQ \times N_{\,\text{exposed}} \leq 10,$$ where $MAF$ is the minor allele frequency, $IQ$ is the SNP imputation quality, and $N_{\,\text{exposed}}$ is the estimated number of observations with a $\text{PM}_{10}$ concentration $> 90\text{th}$ percentile. For each of the approximately 2.5 million SNPs remaining across subpopulations, subpopulation-specific $\text{SNP} \times \text{PM}_{10}$ interaction estimates were adjusted using genomic control, tested for homogeneity (Cochran's Q), and combined using fixed-effects, inverse variance-weighted meta-analysis implemented in METAL ([@c83]). Two-stage, split-sample alternatives (in which subpopulations are grouped into discovery and replication populations) were considered but avoided to maximize statistical power ([@c65]).

Observed genome-wide distributions of meta-analyzed SNP-specific interaction *p*-value were $- \log_{10}$ transformed and compared with those expected under the $\chi^{2}$ distribution using a quantile-quantile (QQ) plot and the genomic inflation factor ($\lambda$) ([@c12]). They were also mapped by chromosomal position to produce Manhattan and regional association plots ([@c48]).

After accounting for linkage disequilibrium (LD) among the approximately 2.5 million SNPs across racially/ethnically diverse subpopulations, a Bonferroni-corrected threshold of $p < 5.0 \times 10^{- 8}$ was used to identify genome-wide significant $\text{SNP} \times \text{PM}_{10}$ interactions ([@c6]; [@c46]). Interaction and standard error estimates of SNPs meeting that threshold were forest plotted and used to compute predicted mean QT (ms) and 95% confidence intervals (95% CIs) by genotype and $\text{PM}_{10}$ concentration, while adjusting for centered covariables. Sensitivity of results also was examined as follows: to lower $\text{PM}_{10}$ thresholds for abnormality (50th--80th percentiles), longer lagged exposure averaging periods (1--4 wk), alternative exposures ($\text{PM}_{2.5}$) ([@c85]), use of $\beta$-antagonists, additional adjustments \[temperature (${^\circ}C$); dew point (${^\circ}C$); barometric pressure (kPa); neighborhood socioeconomic status; smoker status (current, former, never); alcohol drinker status (current, former, never); total caloric intake (kcal); sedentary lifestyle\] and separately, application of Bayesian meta-analytic methods allowing for ancestral population heterogeneity implemented in MANTRA ([@c38]) (genome-wide threshold of importance: $\,{\log\,}_{10}\,\text{Bayes}\,\text{Factor} \geq 6.0$, $\text{probability}\,\text{of}\,\text{heterogeneity} < 0.50$) ([@c68]).

Significant associations identified lead SNPs and variants in LD with them ($r^{2} > 0.8$) for bioinformatic characterization using HaploReg V4 ([@c78]), the UCSC Genome Browser^TM^ ([@c26]), and the WashU Epigenome Browser ([@c88]) with data from the Encyclopedia of DNA Elements Project (ENCODE) ([@c54]) and Roadmap Epigenomics Project ([@c7]). Their characterization involved searching surrounding regions of the cardiac genome (e.g., in cardiomyocytes, cardiac fibroblasts, and heart tissue) for evidence of active or altered transcription.

Results {#s3}
=======

The nine ARIC and WHI subpopulations in this study collectively represented 22,158 participants, of whom 26% were black, 7% were Hispanic, and 22% were male. On average, participants were 64.3 years old and contributed 2.9 ECGs with a mean QT of 402 ms. The two-day mean ($\text{lag}_{0 - 1}$) $\,\text{PM}_{10}$ concentration and its 90th percentile (P90) were $29.9\;\mu g/m^{3}$ and $45.4\;\mu g/m^{3}$, i.e., below NAAQS for $\text{PM}_{10}$ in place at the time of participant examinations ([Table 1](#t1){ref-type="table"}) ([@c72]).

###### 

Characteristics of subpopulations, by study, race/ethnicity, and sex.

Table 1 lists the study names, race/ethnicity, sex, and numbers in the first four columns, respectively; the corresponding mean plus or minus SD for age, ECG, QT, and PM sub 10, with P90 values for PM sub 10, are listed in the other columns.

  Study             Race/ethnicity   Sex ${(m}ean \pm S{D)}$   $n$${(m}ean \pm S{D)}$    Age,*y*${(m}ean \pm S{D)}$   ECGs ${(m}ean \pm S{D)}$   QT, ms ${(m}ean \pm S{D)}$   $PM_{10}\operatorname{,\,}\mu g/m^{3}$^*a*^${(m}ean \pm S{D)}$   P90 ${(m}ean \pm S{D)}$
  ----------------- ---------------- ------------------------- ------------------------ ---------------------------- -------------------------- ---------------------------- ---------------------------------------------------------------- -------------------------
  ARIC              Black            Men                       826                             $57.6 \pm 6.7$              $3.2 \pm 1.0$                $402 \pm 33$                                 $34.4 \pm 12.7$                                    50.3
  ARIC              Black            Women                     1,343                           $57.3 \pm 6.4$              $3.3 \pm 0.9$                $403 \pm 33$                                 $34.3 \pm 12.6$                                    50.9
  ARIC              White            Men                       3,976                           $59.0 \pm 6.5$              $3.5 \pm 0.9$                $406 \pm 31$                                 $33.4 \pm 12.9$                                    49.8
  ARIC              White            Women                     4,462                           $58.5 \pm 6.5$              $3.6 \pm 0.8$                $405 \pm 29$                                 $33.3 \pm 12.9$                                    49.7
  WHI GARNET^*b*^   White            Women                     1,732                           $68.8 \pm 7.1$              $2.5 \pm 0.9$                $401 \pm 30$                                 $27.6 \pm 10.7$                                    41.5
  WHI MOPMAP^*b*^   White            Women                     1,237                           $67.0 \pm 7.0$              $2.7 \pm 0.8$                $402 \pm 30$                                 $27.3 \pm 10.6$                                    41.2
  WHI SHARe         Black            Women                     3,538                           $64.6 \pm 7.1$              $2.4 \pm 0.9$                $400 \pm 33$                                 $28.1 \pm 10.5$                                    41.8
  WHI SHARe         Hispanic         Women                     1,562                           $63.5 \pm 6.7$              $2.5 \pm 0.8$                $400 \pm 30$                                 $29.4 \pm 10.6$                                    43.4
  WHI WHIMS         White            Women                     3,482                           $73.4 \pm 4.5$              $2.4 \pm 0.7$                $400 \pm 30$                                 $26.6 \pm 10.2$                                    39.7
  All               White (67%)      Women (78%)               22,158                               64.3                        2.9                         402                                            29.9                                         45.4

Note: ARIC, Atherosclerosis Risk in Communities study; ECG, electrocardiogram; GARNET, Genomics and Randomized Trials Network; MOPMAP, Modification of PM-Mediated Arrhythmogenesis in Populations; P90, 90th percentile; $\text{PM}_{10}$, particulate matter $< 10\;\mu m$ in diameter; QT, QT interval duration; SD, standard deviation; SHARe, SNP Health Association Resource; WHI, Women's Health Initiative; WHIMS, Women\'s Health Initiative Memory Study.

Range, $5.9–124.3\;\mu g/m^{3}$.

Controls.

Manhattan, regional association, and QQ plots ([Figures 1 and 2](#f1 f2){ref-type="fig"}; see Figure S1) of interaction *p*-value from the trans-ethnic, fixed-effects, inverse variance-weighted meta-analysis identified one genome-wide significant association (rs1619661; $p = 2.11 \times 10^{- 8}$) and 22 subthreshold associations ($5 \times 10^{- 8} < p < 5 \times 10^{- 6}$) across six independent loci ([Table 2](#t2){ref-type="table"}). The lead SNP, rs1619661 is on chromosome 10, approximately 132 kilobase (kb) downstream of *CXCL12* ([Table 2](#t2){ref-type="table"}). This variant's coded allele, *T* (vs. the noncoded allele, *C*), was common among racial/ethnic groups (*T* allele: 81--92%; *CC* genotype: 1.6%, *CT*: 21.8%, *TT*: 76.7%) and associated with QT prolongation in eight (89%) of the nine subpopulations ($P_{\text{Cochran}{'s}\, Q} = 0.14$; [Figure 3](#f3){ref-type="fig"}).

![Manhattan plot of $- \log_{10}$ *p*-value vs. chromosomal position of each SNP from the trans-ethnic, fixed-effects meta-analysis of the $\text{SNP} \times \text{PM}_{10}$ interactions. The red line references the genome-wide significance threshold (*p*-value$< 5.0 \times 10^{- 8}$).](EHP347_f1){#f1}

![Regional plots of the locus, rs1619661, identified by the trans-ethnic, fixed-effects meta-analysis of the $\text{SNP} \times \text{PM}_{10}$ interactions, on chromosome 10, near *CXCL12*. Each point represents the $- \log_{10}$*p*-value of a SNP plotted as a function of its genomic position (build 37) and the genome-wide significance threshold (*p*-value$< 5.0 \times 10^{- 8}$). One SNP reached this threshold. The color coding of all other SNPs indicated linkage disequilibrium with this lead SNP, estimated among Africans (*A*), Ad-mixed Americans (*B*), and Europeans (*C*) from 1000G. Recombination rates were estimated from the 1,000 Genomes Project.](EHP347_f2){#f2}

![Forest plot of $\text{SNP} \times \text{PM}_{10}$ interaction (95% confidence interval) per *T* allele increase in rs1619661 (genotype *CT*) at $\text{PM}_{10}$ concentrations $> 90\text{th}$ percentile, by study, race/ethnicity, and overall ($P_{\text{Cochran}\prime s\,\text{Q}} = 0.14$).](EHP347_f3){#f3}

###### 

Findings from the trans-ethnic, fixed-effects, inverse variance-weighted meta-analysis, including sub-threshold associations ($5 \times 10^{- 8} < p < 5 \times 10^{- 6}$).

Table 2 lists the chromosomes, their positions, lead SNP, and the CA/NCA in the first four columns, respectively; the coded allele frequency for black, Hispanic, and white is listed under the columns that follow. The p-values, interaction estimate (SE), n values, nearest gene, and SNPs are listed under the last four columns, respectively.

  Chr   Position      Lead SNP     CA /NCA   Coded allele Frequency   *p*-value   Interaction Estimate (SE)   $\mathit{n}$             Nearest Gene   SNPs[^*a*^](#t2n1){ref-type="table-fn"}                     
  ----- ------------- ------------ --------- ------------------------ ----------- --------------------------- ------------------------ -------------- ----------------------------------------- ----------------- ---
  10    44,733,383    rs1619661    *T/C*     0.81                     0.92        0.91                        $2.11 \times 10^{- 8}$   2.55 (0.46)    22,158                                    *CXCL12*          8
  22    51,065,600    rs6151412    G/A       0.90                     0.95        0.95                        $1.02 \times 10^{- 6}$   3.88 (0.79)    20,921                                    *ARSA*            1
  8     83,252,586    rs10504754   A/G       0.74                     0.47        0.43                        $1.53 \times 10^{- 8}$   1.54 (0.32)    22,158                                    *SNX16*           1
  7     48,811,506    rs13309098   G/A       0.88                     0.88        0.93                        $1.85 \times 10^{- 6}$   2.37 (0.50)    22,158                                    *ABCA13-CDC14C*   4
  2     213,065,465   rs6725041    *T/C*     0.78                     0.44        0.48                        $2.55 \times 10^{- 8}$   1.52 (0.32)    22,158                                    *ERBB4*           8
  20    39,435,700    rs7361259    *T/C*     0.91                                                             $4.61 \times 10^{- 6}$   5.98 (1.39)    2,169                                     *MAFB*            1

Note: CA, coded allele; CAF, coded allele frequency; Chr, chromosome; NCA, noncoded allele; SE, standard error; SNP, single nucleotide polymorphism.

Total number of significant or sub-threshold SNPs located within the same gene or in LD with the lead SNP ($r^{2} \geq 0.80$).

At $\text{PM}_{10}$ concentrations $> 90\text{th}$ percentile, QT increased 7 ms across the *CC*, *CT*, and *TT* rs1619661 genotypes: from 397 (95% CI: 396, 399) to 401 (400, 401) to 404 (403, 404) ms, but at $\text{PM}_{10}$ concentrations $\leq 90\text{th}$ percentile, QT only increased from 402 (401, 403) to 403 (402, 403) to 403 (403, 403) ms ([Figure 4](#f4){ref-type="fig"}; Table S2). Associations were insensitive to additional adjustment, Bayesian meta-analysis ($\,\log_{10}\,\text{Bayes}\,\text{Factor} = 6.20$; $\text{probability}\,\text{of}\,\text{heterogeneity} = 0.37$), and adoption of a $50 - \mu g/m^{3}$ $\text{PM}_{10}$ threshold, the annual NAAQS for $\text{PM}_{10}$. However, they were attenuated by decreasing $\text{PM}_{10}$ thresholds, increasing lagged exposure averaging periods, substituting $\text{PM}_{2.5}$, and restricting to $\beta$-antagonist users (see Table S3, Figure S2).

![Predicted mean (95% confidence interval) QT (ms) per unit increase in the coded allele (*T*) dosage of rs1619661 at $\text{PM}_{10}$ concentrations $\leq$ and $> 90\text{th}$ percentile (P90), while adjusting for age, geographic region or center, season, calendar year, *RR* interval, and ancestry. *C* allele frequency range: 8--19%.](EHP347_f4){#f4}

In cardiomyocytes, cardiac fibroblasts, and other (including fetal, right atrial, and left/right ventricular) heart tissue, genomic regions surrounding rs1619661 and associated SNPs included deoxyribonuclease (DNAse1) hypersensitivity areas, DNA methylation sites, enhancer/promoter histone marks, and regulatory motifs (see Figure S3 and "TITLE" in Supplemental Material).

Full results from the trans-ethnic, fixed-effects, inverse-variance meta-analysis and rs1619661 characterization using HaploReg Version 4 ([@c78]) and the WashU Epigenome Browser^TM^ ([@c88]) are available at <https://qtgwaspm.web.unc.edu/EHP/> ([@c18]).

Discussion {#s4}
==========

This genome-wide association study (GWAS) of gene--environment interactions discovered a genetic variant associated with increased susceptibility of a racially and geographically diverse population of U.S. men and women to prolonged ventricular repolarization during short-duration ambient PM air pollution exposures below annual and daily thresholds established by the U.S. EPA under the Clean Air Act ([@c72]).

Although we observed a clinically modest, 7-ms increase in QT among persons in the highest $\text{PM}_{10}$ decile with two vs. zero copies of the *T* allele (genotype *TT* vs. *CC*, respectively), the *T* allele of rs1619661 tends to be so common in many U.S. populations that related but seemingly minor population-level shifts in QT may have significant public-health implications. Indeed, upper decile $\text{PM}_{10}$-associated increases in QT exceed the U.S. Food and Drug Administration (FDA) 5-ms threshold used in premarket evaluation of drug safety ([@c73]), an increase that may also carry cardiovascular disease morbidity and mortality risk ([@c86]).

The attendant cardiovascular risks are plausibly related to *CXCL12* ([Table 2](#t2){ref-type="table"})---the locus most proximate to rs1619661---which has been implicated in, for example, GWAS of coronary artery disease ([@c55]) and early-onset myocardial infarction ([@c24]). *CXCL12* encodes stromal cell-derived factor 1 (SDF1), an evolutionarily conserved chemokine that is expressed in cardiomyocytes ([@c49]) and is induced by pro-inflammatory stimuli, including particulate exposures ([@c33]). SDF1 binds to *CXCR4*, a seven-transmembrane, G-protein coupled receptor that is widely distributed on cardiomyocytes and neurons.

In those cell types, the ligand-receptor complex inhibits $\beta$-adrenergically activated calcium influx through the L-type ${Ca}^{2 +}$ ion channel ([@c49]), recently implicated in the largest GWAS of QT to date ([@c3]). Resultant shortening of the ventricular action potential (Phase 2) and its electrocardiographic manifestation, QT interval duration, was apparent in the present study among persons in the highest $\text{PM}_{10}$ decile with the *C* allele \[i.e., those individuals with the *CC* or *CT* (vs. *TT*) genotype\]. Although contrary to PM-associated increases in QT duration observed in prior studies ([@c32]; [@c37]; [@c75]), this group represents only a minority of the study population. Likewise, its reversibility was reflected, albeit in this observational epidemiologic context, by the attenuation of the observed $\text{SNP} \times \text{PM}_{10}$ interaction among users of $\beta$-adrenergic antagonists, the first-line therapy in long-QT syndromes ([@c27]).

The $\text{SNP} \times \text{PM}_{10}$ interaction also was attenuated at longer lagged exposure averaging periods in this context. This form of attenuation highlights the potential role of $\beta$-adrenergic receptor-mediated blunting of sympathetic nervous system responses to chronic PM exposure. Indeed, sympathetic responses of the heart to stressors are mediated by the binding of catecholamines to cardiac $\beta$-adrenergic receptor s, the density, sensitivity, and activity of which decrease with chronic stress exposure ([@c25]; [@c70]). Chronic stress exposures also lead to adaptive changes of neural and glial cells in the central nervous system ([@c35]), which controls the heart via innervation of the sinoatrial node. The attenuated interactions that we observed herein may thereby reflect physiologically desensitizing adaptations to longer-term PM exposures.

However, several limitations apply to the study of gene-environment interaction in genome-wide contexts, e.g., low power and overestimation of observed effect sizes in hypothesis-generating discovery efforts ([@c19]). To increase power, we used all nine subpopulations in the discovery effort. To further increase power, we used generalized estimating equations methods to leverage repeated measures of QT and $\text{PM}_{10}$ among 22,158 participants from two well-characterized, multi-ethnic, and environmentally diverse cardiovascular disease cohorts. Furthermore, we established homogeneity and robustness of $\text{SNP} \times \text{PM}_{10}$ interaction estimates among the cohorts, subpopulations, and races/ethnicities in meta-analyses, which were also subjected to additional adjustment for meteorological, neighborhood-socioeconomic, and lifestyle characteristics. Finally, the trans-ethnic, fixed-effects, inverse variance-weighted meta-analysis discovered a genome-wide significant interaction in data that also provided convincing evidence of association in a Bayesian meta-analysis that allowed for racial/ethnic heterogeneity, where the interaction was found to be 1.6 million times more likely under the alternative to the null hypothesis of no association.

The 132-kb separation of rs1619661 and *CXCL12* also limits the biological plausibility of their role in PM-associated QT prolongation. However, causal genes that are megabases away from GWAS-implicated lead SNPs have been identified in other settings ([@c39]; [@c66]). For example, obesity-associated SNPs within the well-known *FTO* locus directly interact with promoter regions of *IRX3* that are approximately 500 kb downstream. In fact, *IRX3*, which is causally linked to body mass and composition, participates in long-range interactions across a relatively large, 2-megabase region ([@c50]; [@c66]). We also identified potentially active or altered transcription in regions of the cardiac genome surrounding rs1619661 and its associated SNPs with data from ENCODE. Although it is unclear whether these regions are functionally linked to *CXCL12*, it is plausible because of important, long-range (i.e., $\sim 120\,\text{kb}$) mechanisms of distal gene regulation ([@c57]). Nevertheless, expression assays are needed to confirm the proposed link between the rs1619661 locus and *CXCL12*.

Replication---a suggested gold standard for validating GWAS of main genetic effects---poses a particular challenge for gene-environment interaction studies like the one described here ([@c4]; [@c5]; [@c23]; [@c71]). The extent of the challenge is related to the need for similarly powered populations with equally well-harmonized outcomes and exposures, even if they are, e.g., rare, difficult to measure, or peculiar to racial/ethnic minority populations poorly represented in large-scale GWAS to date. In the present study, a well-powered, independent replication was not feasible, given the limited availability of populations with high-quality, 12-lead ECGs; national-scale, kriged daily mean $\text{PM}_{10}$ concentrations; and genome-wide SNP data. Moreover, functional validation in model organisms ([@c16]; [@c69]) was beyond the scope of the original project. We therefore view this discovery effort as hypothesis-generating, and given the importance of replication in protecting against type-1 error ([@c63]), we have provided publicly accessible summary statistics (<https://qtgwaspm.web.unc.edu/EHP/>) to facilitate functional validation and external replication as additional data become available.

Although not reaching genome-wide significance, the subthreshold loci identified herein ([Table 2](#t2){ref-type="table"}) may also warrant scrutiny*. ARSA* (rs6151412, synonymous) and *ERBB4* (rs6725041, intronic) are particularly compelling in this setting due to their functional role in ${Ca}^{2 +}$ transport ([@c8]; [@c53]). *ERBB4* has additionally been associated with cardiac myopathy ([@c15]), coronary artery calcification ([@c84]), and cardiomyocyte proliferation ([@c77]). *SNX16* (rs10504754, 498 kb upstream) has been associated with heart failure ([@c67]). *MAFB* (rs7361259, 118 kb upstream) has been implicated in a gene--drug interaction GWAS of rheumatoid arthritis, an inflammatory disorder associated with QT prolongation ([@c10]). *ABCA13-CDC14C* (rs13309098; 124-137 kb downstream) currently has no established link with cardiovascular disease.

Conclusions {#s5}
===========

We conclude that genetic variation may modify susceptibility to $\text{PM}_{10}$-associated QT prolongation, and pending further follow-up, cautiously postulate changes in L-type ${Ca}^{2 +}$ ion channel activity triggered by inflammatory responses to PM exposure as a possible mechanism. In lieu of such possibilities, previously hypothesized genetic, inflammatory, and neural mechanisms of PM-mediated arrhythmogenesis would remain largely distinct. The Clean Air Act mandates setting of NAAQS for PM that protect sensitive populations---including persons with innate factors that may increase vulnerability to PM-associated disease. Although we cannot unequivocally link genetic variation to PM-associated QT prolongation, we did discover a biologically plausible variant that may confer susceptibility, a finding that must undergo replication and functional characterization in future studies.

Supplemental Material
=====================

###### 
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